-
Mashup Score: 5
Clinical trials in adults conducted within the National Cancer Institute’s (NCI’s) National Clinical Trials Network (NCTN) over the last four decades are estimated to have extended the lives of patients with cancer in the U.S. by at least 14.2 million life-years, according to a new analysis. Importantly, the study estimated that the costs of those gains have been quite modest: roughly $326 in…
Source: medicalxpress.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 1Lung Cancer Screening using LDCT | Cancer Screening Committee - 1 year(s) ago
Lung cancer is the leading cause of cancer-related deaths. Around 3,300 people die from it every year in Switzerland. Tobacco smoking is by far the leading risk factor for lung cancer, accounting for about 80-90% of lung cancer diagnoses. In view of the high burden of the disease, there is a national and international debate on whether low-dose CT (LDCT) screening for lung cancer should be…
Source: Cancer Screening Committee |Categories: Hem/Oncs, Latest HeadlinesTweet-
The Swiss Cancer Screening Committee suggests offering LDCT lung cancer screening to people at risk @myESMO @IASLC @thoracic @ESTRO_RT @ASCOPost @AebiSP https://t.co/Z80dA5hg4m
-
-
Mashup Score: 0Lung Cancer Screening using LDCT | Cancer Screening Committee - 1 year(s) ago
Lung cancer is the leading cause of cancer-related deaths. Around 3,300 people die from it every year in Switzerland. Tobacco smoking is by far the leading risk factor for lung cancer, accounting for about 80-90% of lung cancer diagnoses. In view of the high burden of the disease, there is a national and international debate on whether low-dose CT (LDCT) screening for lung cancer should be…
Source: Cancer Screening Committee |Categories: Hem/Oncs, Latest HeadlinesTweet-
The Swiss Cancer Screening Committee suggests offering LDCT lung cancer screening to people at risk #SOHC22 @krebsliga @lungenliga https://t.co/Z80dA5gIeO
-
-
Mashup Score: 1
All experts involved in the development of these Guidelines have submitted declarations of interest. These have been compiled in a report and published in a sup
Source: OUP AcademicCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @drkpavithran: 2022 Cardio-oncology guidelines by European society of cardiology https://t.co/EgNRKXO1SR https://t.co/YUURVgYJlo
-
-
Mashup Score: 1
Truncation of exon 18 of FGFR2 (FGFR2ΔE18) is a potent driver mutation in mice and humans, and FGFR-targeted therapy should be considered for patients with cancer expressing stable FGFR2ΔE18 variants.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @gerlach_d: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers | Nature https://t.co/pgs3hB5Gi7
-
-
Mashup Score: 0Roche’s subcutaneous formulation of Tecentriq demonstrates positive Phase III results - 2 year(s) ago
IMscin001 study showed non-inferior levels of cancer immunotherapy Tecentriq in the blood, when injected subcutaneously, compared to intravenous infusion, in people with advanced non-small cell lung…
Source: www.roche.comCategories: Hem/Oncs, Latest HeadlinesTweet-
New study supports SQ formulation of Atezolizumab https://t.co/7ZIIflveEN
-
-
Mashup Score: 23
Swiss Heart Failure Working Group of the Swiss Society of Cardiology
Source: www.heartfailure.chCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @SwissCardio: 📢 #SwissCardio booklet on #CardioOncology is officially out 🎉 👀 Download: https://t.co/q9VKWcEq8p @escardio @SwissCardio…
-
-
Mashup Score: 10Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Stage IIIA NSCLC Overall Survival and Biomarker Analyses - The ASCO Post - 2 year(s) ago
By Matthew Stenger Posted: 5/31/2022 11:56:00 AM Last Updated: 5/31/2022 11:46:10 AM In analyses from a Spanish phase II trial (NADIM) reported in the Journal of Clinical Oncology, Provencio et al found a high rate of 3-year overall survival in patients with operable stage…
Source: ascopost.comCategories: Latest Headlines, Oncologists2Tweet-
RT @MARIANOPROVENCI: Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Stage IIIA NSCLC - The ASCO Post - https://t.co/VjRALso9pR #Goog…
-
-
Mashup Score: 0
Pembrolizumab is likely to be cost-effective from the Swiss healthcare payer perspective, whereas pembrolizumab plus chemotherapy is not.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
@peters_solange Yes I am! https://t.co/KpKQ8cqSFo
-
@DrRiyazShah CEA also favors mono https://t.co/KpKQ8cqSFo
-
-
Mashup Score: 3
Editorial from The New England Journal of Medicine — Expanding Horizons for Treatment of Early-Stage Lung Cancer
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @VivekSubbiah: Expanding Horizons for Treatment of Early-Stage Lung Cancer | NEJM https://t.co/a8DvVMVB81
-
RT @VivekSubbiah: Four decades of clinical trials: 14.2 million life-years gained, at $326 per year https://t.co/6UvHqvHbI3